Completed

Usher Syndrome - Clinical and Molecular Studies

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Who is being recruted

Congenital Abnormalities+22

+ Abnormalities, Multiple

+ Blindness

See all eligibility criteria
How is the trial designed

Observational
Study Start: June 1993
See protocol details

Summary

Principal SponsorNational Eye Institute (NEI)
Last updated: March 4, 2008
Sourced from a government-validated database.Claim as a partner

Study start date: June 1, 1993

Actual date on which the first participant was enrolled.

The Usher Syndromes (USH), characterized by autosomal recessive inheritance, are genotypically distinct diseases which share specific phenotypic characteristics. Affected individuals have congenital neurosensory hearing impairment of variable severity and a progressive pigmentary retinal degeneration commonly referred to as retinitis pigmentosa. Interfamilial differences in USH patients are greater than intrafamilial differences and investigators have proposed at least two distinct phenotype types; Usher Syndrome type 1 (USH 1) and Usher Syndrome type 2 (USH 2) (Fishman 1983). Patients with USH 1 are profoundly deaf from birth, have unintelligible speech and absent vestibular function. Nightblindness is apparent in the 1st or 2nd decade accompanied by an extinguished electroretinogram (ERG) and profound loss of visual field. Patients with USH 2 can have moderate to severe hearing loss and normal vestibular function. Nightblindness occurs in the 2nd or 3rd decade, there is variable field loss and variable response by the ERG (Fishman 1983). Heterogeneity has been verified by linkage studies and at least three USH 1 loci and two USH 2 loci are known (Kimberling et al 1990; Lewis et al 1990; Kaplan et al 1992; Smith et al 1992a.) With increasingly sophisticated clinical testing, subtle differences may permit a more accurate distinction between the two USH phenotypes. The purpose of this study is to classify as accurately as possible these patients' clinical features by careful audiologic, vestibular, psychophysical and electrodiagnostic testing and correlate these with the genetic mutations identified through linkage studies and eventually to the genes (genetic mutations) as they become identified.

NCT00001347
Principal SponsorNational Eye Institute (NEI)
Last updated: March 4, 2008
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

200 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Congenital AbnormalitiesAbnormalities, MultipleBlindnessDeafnessEar DiseasesEye DiseasesHearing DisordersHearing Loss, SensorineuralCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesNervous System DiseasesNeurologic ManifestationsOtorhinolaryngologic DiseasesRetinal DegenerationRetinal DiseasesSensation DisordersSigns and SymptomsPathological Conditions, Signs and SymptomsVision DisordersEye Diseases, HereditaryGenetic Diseases, InbornHearing LossDeaf-Blind DisordersRetinal DystrophiesRetinitis PigmentosaUsher Syndromes

Criteria

Inclusion Criteria: Patients must have documentation of neurosensory hearing loss and retinitis pigmentosa and fulfill the clinical characteristics (Table) as accepted for USH 1 and USH 2. The minimal test battery will identify all patients with USH 1 and USH 2 as well as possible subtypes. Candidates will be recruited from lists of patients willing to participate in research studies compiled by the R.P. Foundation, and by referral from their private physicians. On occasion additional family members will be studied after an initial individual is ascertained as above. No patients with intrauterine and childhood infections, and intrauterine and birth complications can result in trauma to both the auditory or visual system and a positive history for these conditions will necessitate exclusion from the study.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

National Eye Institute (NEI)

Bethesda, United StatesOpen National Eye Institute (NEI) in Google Maps
CompletedOne Study Center